Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2018: Focus on Monoclonal Antibodies, Murine mAb, Chimeric mAb, Humanized mAb & Human aAb
DUBLIN, Feb. 6, 2019 /PRNewswire/ --
The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The Global Cancer Monoclonal Antibody Partnering 2012-2018: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
-- Monoclonal antibodies
-- Murine mAb
-- Chimeric mAb
-- Humanized mAb
-- Human aAb
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Key benefits
-- In-depth understanding of cancer monoclonal antibody deal trends since
2012
-- Access to headline, upfront, milestone and royalty data
-- Access to the structure of cancer monoclonal antibody agreements with
numerous real life case studies
-- Comprehensive access to over 360 actual cancer monoclonal antibody deals
entered into by the world's biopharma companies
-- Identify most active companies in cancer monoclonal antibody partnering
-- Insight into the terms included in a cancer monoclonal antibody
agreement, together with real world clause examples
-- Understand the key deal terms companies have agreed in previous deals
-- Undertake due diligence to assess suitability of your proposed deal
terms for partner companies
-- Spot the emerging companies in the cancer monoclonal antibody area
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Most active Cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody partnering by deal type
2.5. Cancer monoclonal antibody partnering by therapy area
2.6. Deal terms for Cancer monoclonal antibody partnering
2.6.1 Cancer monoclonal antibody partnering headline values
2.6.2 Cancer monoclonal antibody deal upfront payments
2.6.3 Cancer monoclonal antibody deal milestone payments
2.6.4 Cancer monoclonal antibody royalty rates
Chapter 3 - Leading Cancer monoclonal antibody deals
3.1. Introduction
3.2. Top Cancer monoclonal antibody deals by value
Chapter 4 - Most active Cancer monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active Cancer monoclonal antibody dealmakers
4.3. Most active Cancer monoclonal antibody partnering company profiles
Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory
Chapter 6 - Cancer monoclonal antibody dealmaking by technology type
Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Cancer monoclonal antibody deals by company A-Z
Appendix 2 - Cancer monoclonal antibody deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Cancer monoclonal antibody deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Cancer monoclonal antibody deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/research/c6xvtb/global_cancer?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
